GPT and Hypertension: In the KEYNOTE-564 30-months follow-up analysis, 32% of patients in the pembrolizumab group versus 18% of patients in the placebo group presented grade 3 or worse AEs, with hypertension and increased alanine aminotransferase being the most frequent in the treated group; 21% of patients in the pembrolizumab group discontinued treatment due to AEs (Powles et al. 2022).